Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

News & Events

Statement in Response to COVID-19 from Nuventra Pharma Sciences

As a company committed to helping our clients bring new medicines to patients in need, we have been closely monitoring the global spread of the novel coronavirus COVID-19.

During a global pandemic, it is critical for organizations across the world, especially in the pharmaceutical / biotech industries, to work together to ensure public safety, contain the spread of the disease and develop vaccines or therapies that target the disease.

At Nuventra, the safety of our team members, their families and our clients is paramount. We have implemented measures to address safety and contain the spread of the disease while limiting the impact on the ongoing support we offer clients. Our employees have been prohibited from traveling for business purposes. Nuventra’s offices are closed and employees are currently required to work from home. We do not expect any disruption to our usual business practices

Finally, we want to help our clients bring vaccines and therapies to patients in need as soon as possible. An important resource Nuventra offers is bandwidth. With the increased urgency to address the current outbreak, we have services to offer immediately. We can quickly support the development of a vaccine or treatment – from data analysis and pharmacometric modeling to help identify dosing paradigms to writing, programming and regulatory strategy.

In addition, we will offer the following services free of charge for any drug development program intended to prevent or treat the novel coronavirus:

  • Review of clinical protocols
  • High level drug development gap analysis
  • General 30-minute Q&A with Nuventra drug development professionals (including former FDA reviewers) to help address any roadblocks or issues in the development of a vaccine or treatment